# EDGAR Filing Document

**Accession Number:** 0001724521
**File Stem:** 0000950170-23-005155
**Filing Date:** 2023-2
**Character Count:** 18250
**Document Hash:** aab39d683cc961fa6d6b3e0ff833b0e8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000950170-23-005155.hdr.sgml**: 20230228

**ACCESSION NUMBER**: 0000950170-23-005155

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 5

**FILED AS OF DATE**: 20230228

**DATE AS OF CHANGE**: 20230228

**EFFECTIVENESS DATE**: 20230228

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Arcus Biosciences, Inc.
- **CENTRAL INDEX KEY:** 0001724521
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 473898435
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-270114
- **FILM NUMBER:** 23686223

**BUSINESS ADDRESS:**
- **STREET 1:** 3928 POINT EDEN WAY
- **CITY:** HAYWARD
- **STATE:** CA
- **ZIP:** 94545
- **BUSINESS PHONE:** (510) 694-6200

**MAIL ADDRESS:**
- **STREET 1:** 3928 POINT EDEN WAY
- **CITY:** HAYWARD
- **STATE:** CA
- **ZIP:** 94545

**As filed with the Securities and Exchange Commission on February 28, 2023**

**Registration No. 333-** 

------

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

------

**FORM S-8**

**REGISTRATION STATEMENT**

**Under**

**The Securities Act of 1933**

------

**Arcus Biosciences, Inc.**

**(Exact name of Registrant as specified in its charter)**

------

---

| | |
|:---|:---|
| **Delaware** | **47-3898435** |
| **(State or other jurisdiction of**<br>**incorporation or organization)** | **(IRS Employer**<br>**Identification No.)** |

---

**3928 Point Eden Way**

**Hayward, CA 94545**

**(Address of Principal Executive Offices, Zip Code)**

------

**ARCUS BIOSCIENCES, INC. 2018 EQUITY INCENTIVE PLAN**

**ARCUS BIOSCIENCES, INC. 2018 EMPLOYEE STOCK PURCHASE PLAN**

**(Full title of plan)**

------

**Terry Rosen, Ph.D.**

**Chief Executive Officer**

**Arcus Biosciences, Inc.**

**3928 Point Eden Way**

**Hayward, CA 94545**

**(Name and address of agent for service)**

**(510) 694-6200**

**(Telephone number, including area code, of agent for service)**

**Please send copies of all communications to:**

**Kenneth L. Guernsey**

**Cooley LLP**

**101 California Street, 5**<sup>th</sup> **Floor**

**San Francisco, CA 94111**

**(415) 693-2000**

------

Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐  |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐  |
|  |  | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐.

------

**EXPLANATORY NOTE**

Pursuant to General Instruction E to Form S-8, this Registration Statement is being filed with the U.S. Securities and Exchange Commission (the "Commission") for the purpose of registering an additional number of securities of the same class as other securities for which a Registration Statement on Form S-8 relating to the same employee benefit plans is effective. Specifically, this Registration Statement is being filed to register (i) 2,916,602 additional shares of common stock of Arcus Biosciences, Inc. (the "Registrant") for issuance under the Arcus Biosciences, Inc. 2018 Equity Incentive Plan and (ii) 729,150 additional shares of common stock of the Registrant for issuance under the Arcus Biosciences, Inc. 2018 Employee Stock Purchase Plan, in each case, pursuant to the provisions of such plans that provide for automatic annual increases in the number of shares reserved for issuance thereunder. This Registration Statement hereby incorporates by reference the contents of the Registrant's Registration Statements on Form S-8 filed with the Commission on March 16, 2018 (File No. 333-223746), March 5, 2019 (File No. 333-230074), March 5, 2020 (File No. 333-236915), February 25, 2021 (File No. 333-253474) and February 23, 2022 (File No. 333-262929) (the "Prior Forms S-8") pursuant to General Instruction E to Form S-8.

**PART II**

**Information Required in the Registration Statement**

**Item 3. Incorporation of Documents by Reference**

The Registrant hereby incorporates by reference into this Registration Statement the Prior Forms S-8 and the following documents previously filed with the SEC:

(a) the Registrant's Annual Report on Form [10-K](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001724521/000095017023005112/rcus-20221231.htm) for the year ended December 31, 2022, filed with the SEC on February 28, 2023; and

(b) the description of the Registrant's common stock contained in the Registrant's Registration Statement on [Form 8-A](https://www.sec.gov/Archives/edgar/data/1724521/000119312518077572/d461416d8a12b.htm) (File No. 001-38419), filed with the SEC on March 9, 2018, including any amendments or reports filed for the purpose of updating such description, including Exhibit 4.2 to the Registrant's Annual Report on Form 10-K filed with the SEC on February 21, 2021.

All other reports and documents filed by the Registrant pursuant to Section 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the "<u>Exchange Act</u>") subsequent to the filing of this Registration Statement and prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which de-registers all securities then remaining unsold shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents. The Registrant is not, however, incorporating any documents or information that the Registrant is deemed to furnish and not file in accordance with SEC rules. Any statement contained in a document incorporated or deemed incorporated by reference in this Registration Statement will be deemed modified or superseded for purposes of this Registration Statement to the extent that a statement contained in any subsequently filed document that also is deemed incorporated by reference in this Registration Statement modifies or supersedes that statement.

------

**Item 8. Exhibits**

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
|  |  | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** | **Incorporated by Reference** |  |
| **Exhibit**<br>**Number** | **Description** | **Form** | **File No.** | **Exhibit** | **Filing<br>Date** | **Filed<br>Herewith** |
| &nbsp;&nbsp;&nbsp;&nbsp;4.1 | [Amended and Restated Certificate of Incorporation of Registrant.](https://www.sec.gov/Archives/edgar/data/1724521/000156459018012447/rcus-ex31_541.htm) | 10-Q | 001-38419 | 3.1 | 5/9/2018 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;4.2 | [Amended and Restated Bylaws of Registrant.](https://www.sec.gov/Archives/edgar/data/1724521/000156459020026867/rcus-ex31_7.htm) | 8-K | 001-38419 | 3.1 | 5/26/2020 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;5.1 | [Opinion of Cooley LLP.](rcus-ex5_1.htm) |  |  |  |  | X |
| 23.1 | [Consent of Independent Registered Public Accounting Firm.](rcus-ex23_1.htm) |  |  |  |  | X |
| 23.2 | Consent of Cooley LLP (contained in Exhibit 5.1). |  |  |  |  | X |
| 24.1 | [Power of Attorney (contained in the signature page hereto).](#power_of_attorney) |  |  |  |  | X |
| 99.1 | [Arcus Biosciences, Inc. 2018 Equity Incentive Plan.](https://www.sec.gov/Archives/edgar/data/1724521/000119312518069517/d317356dex103.htm) | S-1/A | 333-223086 | 10.3 | 3/5/2018 |  |
| 99.2 | [Arcus Biosciences, Inc. 2018 Employee Stock Purchase Plan.](https://www.sec.gov/Archives/edgar/data/1724521/000119312518069517/d317356dex104.htm) | S-1/A | 333-223086 | 10.4 | 3/5/2018 |  |
| 107 | [Filing Fee Table.](rcus-exfiling_fees.htm) |  |  |  |  | X |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Hayward, State of California on this 28<sup>th</sup> day of February, 2023.

---

| | |
|:---|:---|
| **ARCUS BIOSCIENCES, INC.** | **ARCUS BIOSCIENCES, INC.** |
| By: | /s/ Terry Rosen |
|  | Terry Rosen, Ph.D.<br>Chief Executive Officer |

---

**<u>PO</u><u>WER OF ATTORNEY</u>**

**KNOW ALL PERSONS BY THESE PRESENTS** that each person whose signature appears below constitutes and appoints Terry Rosen, Ph.D. and Juan Carlos Jaen, Ph.D. and each of them, his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this registration statement, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that each of said attorney-in-fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue hereof.

**IN WITNESS WHEREOF**, each of the undersigned has executed this Power of Attorney as of the date indicated.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

------

---

| | | |
|:---|:---|:---|
| **Name** | **Title** | **Date** |
| /s/ Terry Rosen | Chief Executive Officer and Director | February 28, 2023 |
| **Terry Rosen, Ph.D.** | (Principal Executive Officer) |  |
| /s/ Juan Carlos Jaen | President and Director  | February 28, 2023 |
| **Juan Carlos Jaen, Ph.D.** |  |  |
| /s/ Jennifer Jarrett | Chief Operating Officer and Director | February 28, 2023 |
| **Jennifer Jarrett** |  |  |
| /s/ Robert C. Goeltz II | Chief Financial Officer | February 28, 2023 |
| **Robert C. Goeltz II** | (Principal Financial and Accounting Officer) |  |
| /s/ Kathryn Falberg | Director | February 28, 2023 |
| **Kathryn Falberg** |  |  |
| /s/ Linda Higgins | Director | February 28, 2023 |
| **Linda Higgins, Ph.D.** |  |  |
| /s/ Yasunori Kaneko | Director | February 28, 2023 |
| **Yasunori Kaneko, M.D.** |  |  |
| /s/ David Lacey | Director | February 28, 2023 |
| **David Lacey, M.D.** |  |  |
| /s/ Nicole Lambert | Director | February 28, 2023 |
| **Nicole Lambert** |  |  |
| /s/ Patrick Machado | Director | February 28, 2023 |
| **Patrick Machado, J.D.** |  |  |
| /s/ Merdad Parsey | Director | February 28, 2023 |
| **Merdad Parsey, M.D., Ph.D.** |  |  |
| /s/ Andrew Perlman | Director | February 28, 2023 |
| **Andrew Perlman, M.D., Ph.D.** |  |  |
| /s/ Antoni Ribas | Director | February 28, 2023 |
| **Antoni Ribas, M.D., Ph.D.** |  |  |

---

------

## Ex-5

**Exhibit 5.1**

![img39946569_0.jpg](img39946569_0.jpg)

Kenneth L. Guernsey

T: +1 415 693 2091

kguernsey@cooley.com

February 28, 2023

Arcus Biosciences, Inc.<br>3928 Point Eden Way<br>Hayward, CA 94545

Ladies and Gentlemen:

We have acted as counsel to Arcus Biosciences, Inc. (the "**Company**"), a Delaware corporation, in connection with the filing of a Registration Statement on Form S-8 (the "**Registration Statement**") with the Securities and Exchange Commission (the "**Commission**") covering the offering of up to 3,645,752 shares (the "**Shares**") of the Company's Common Stock, $0.0001 par value ("**Common Stock**"), consisting of (a) 2,916,602 shares of Common Stock issuable pursuant to the Company's 2018 Equity Incentive Plan (the "**2018 EIP**"), and (b) 729,150 shares of Common Stock issuable pursuant to the Company's 2018 Employee Stock Purchase Plan (together with the 2018 EIP, the "**Plans**").

In connection with this opinion, we have examined and relied upon the Registration Statement and related prospectus, the Company's certificate of incorporation and bylaws, each as currently in effect, the Plans, and originals or copies certified to our satisfaction of such other records, documents, certificates, memoranda and other instruments as in our judgment are necessary or appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as copies, the accuracy, completeness and authenticity of certificates of public officials and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters.

Our opinion is expressed only with respect to the General Corporation Law of the State of Delaware. We express no opinion to the extent that any other laws are applicable to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation.

On the basis of the foregoing, and in reliance thereon, we are of the opinion that the Shares, when sold and issued in accordance with the Plans, the Registration Statement and related prospectuses, will be validly issued, fully paid and nonassessable (except as to shares issued pursuant to certain deferred payment arrangements, which will be fully paid and nonassessable when such deferred payments are made in full).

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act of 1933, as amended, or the rules and regulations of the Commission thereunder.

Very truly yours,

**Cooley LLP**

By: <u>/s/ Kenneth Guernsey</u> 

&nbsp;&nbsp;&nbsp;&nbsp; Kenneth Guernsey

101 California Street, 5th Floor, San Francisco, CA 94111-5800 T: (415) 693-2000 F: (415) 693-2222 www.cooley.com

------

## Ex-23

**Exhibit 23.1**

**Consent of Independent Registered Public Accounting Firm**

We consent to the incorporation by reference in the Registration Statement (Form S-8) pertaining to the Arcus Biosciences, Inc. 2018 Equity Incentive Plan and the Arcus Biosciences, Inc. 2018 Employee Stock Purchase Plan, of our reports dated February 28, 2023, with respect to the consolidated financial statements of Arcus Biosciences, Inc. and the effectiveness of internal control over financial reporting of Arcus Biosciences, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2022, filed with the Securities and Exchange Commission.

/s/ Ernst & Young LLP

San Mateo, California <br>February 28, 2023

------

## Ex-Filing

**Exhibit 107**

**Calculation of Filing Fee Table** 

**Form S-8**

**(Form Type)**

**Arcus Biosciences, Inc.**

**(Exact name of Registrant as specified in its charter)**

**Table 1: Newly Registered Securities**

---

| | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|
| **Security Type** | **Title of Securities**<br>**to be Registered** | **Fee Calculation Rule** | **Amount**<br>**to be<br>Registered(1)** | **Proposed<br>Maximum<br>Offering Price<br>Per Share** | **Proposed<br>Maximum<br>Aggregate**<br>**Offering Price** | **Fee Rate** | **Amount of**<br>**Registration Fee** |
| Equity | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the Arcus Biosciences, Inc. 2018 Equity Incentive Plan | Other(3) | 2916602 (2) | $18.43 (3) | $53752974.86 | $110.20 per<br>$1,000,000<br>| $5923.58 |
| Equity | Common Stock, $0.0001 par value per share, reserved for issuance pursuant to the Arcus Biosciences, Inc. 2018 Employee Stock Purchase Plan | Other(5) | 729150 (4) | $15.67 (5) | $11425780.50 | $110.20 per<br>$1,000,000<br>| $1259.12 |
|  | **TOTAL** |  | 3645752  |  | $65178755.36 |  | $7182.70 |

---

(1) Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the " <u>Securities Act</u> "), this Registration Statement shall also cover any additional shares of Registrant's common stock that become issuable under the plans set forth herein as a result of any stock dividend, stock split, recapitalization, or other similar transaction effected without the receipt of consideration that results in an increase to the number of outstanding shares of Registrant's common stock, as applicable.

(2) Represents additional shares of common stock available for issuance under the Arcus Biosciences, Inc. 2018 Equity Incentive Plan pursuant to the evergreen provisions of such plan.

(3) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) and (h) under the Securities Act and based upon the average of the high and low prices of the Registrant's common stock as reported on the New York Stock Exchange on February 24, 2023.

(4) Represents additional shares of common stock available for issuance under the Arcus Biosciences, Inc. 2018 Employee Stock Purchase Plan pursuant to the evergreen provisions of such plan.

(5) Estimated solely for the purpose of calculating the registration fee in accordance with Rule 457(c) and (h) under the Securities Act and based upon the average of the high and low prices of the Registrant's common stock as reported on the New York Stock Exchange on February 24, 2023, multiplied by 85%.

------